Search results
Results from the WOW.Com Content Network
APHL HIV-1 RNA Test Results Reporting Guide | 1 This document outlines the importance of accurately reporting results from quantitative HIV-1 RNA assays. Patient samples that have HIV-1 RNA concentrations that are below the lower limit of quantitation (LLoQ) and above
HIV-1 RNA, Quantitative, Real-Time PCR - This test is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HIV-1 infected patients.
Labcorp test details for Human Immunodeficiency Virus 1 (HIV-1), Quantitative, Real-time PCR (Nongraphical)
The HIV-1/HIV-2 Qualitative test detects the presence of HIV-1 and/or HIV-2 RNA, whereas the HIV-1 Quant Dx Assay and the HIV-1 Assay detect the presence of HIV-1 RNA. The intended use of the HIV-1/HIV-2 Qualitative test also extends to HIV-2 confirmation.
Human immunodeficiency virus type 1 (HIV-1) RNA can be measured using qualitative or quantitative techniques. Qualitative testing (commonly referred to as nucleic acid testing or NAT) is used as a screening test to identify HIV-infected individuals, such as screening possible blood donors.
The Abbott RealTime HIV-1 assay is intended for use in conjunction with clinical presentation and other laboratory markers for disease prognosis and for use as an aid in assessing viral response to antiretroviral treatment as measured by changes in plasma HIV-1 RNA levels.
Quantitative HIV-1 RNA level in plasma (ie, HIV-1 viral load) is an important surrogate marker in assessing the risk of disease progression and monitoring response to anti-HIV-1 drug therapy in the routine medical care of individuals living with HIV-1.
Polymerase chain reaction (PCR) tests are used to detect HIV's genetic material, called RNA. These tests can be used to screen the donated blood supply and to detect very early infections before antibodies have been developed. This test may be performed just days or weeks after exposure to HIV.
Quantitative HIV-1 RNA level in plasma (ie, HIV-1 viral load) is an important surrogate marker in assessing the risk of disease progression and monitoring response to anti-HIV-1 drug therapy in the routine medical care of HIV-1-infected patients.
HIV infection is identified either by the detection of HIV-specific antibodies in serum or plasma or by demonstrating the presence of the virus by nucleic acid detection using polymerase chain reaction (PCR), p24 antigen testing or, rarely these days, by growing virus in cell culture.